Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations

In cancer research, the accuracy of the technology used for biomarkers detection is remarkably important. In this context, digital PCR represents a highly sensitive and reproducible method that could serve as an appropriate tool for tumor mutational status analysis. In particular, droplet-based digital PCR approaches have been developed for detection of tumor-specific mutated alleles within plasmatic circulating DNA. Such an approach calls for the development and validation of a very significant quantity of assays, which can be extremely costly and time consuming. Herein, we evaluated assays for the detection and quantification of various mutations occurring in three genes often misregulated in cancers: the epidermal growth factor receptor (EGFR), the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and the Tumoral Protein p53 (TP53) genes. In particular, commercial competitive allele-specific TaqMan® PCR (castPCR™) technology, as well as TaqMan® and ZEN™ assays, have been evaluated for EGFR p.L858R, p.T790M, p.L861Q point mutations and in-frame deletions Del19. Specificity and sensitivity have been determined on cell lines DNA, plasmatic circulating DNA of lung cancer patients or Horizon Diagnostics Reference Standards. To show the multiplexing capabilities of this technology, several multiplex panels for EGFR (several three- and four-plexes) have been developed, offering new "ready-to-use" tests for lung cancer patients.

[1]  Meizhuo Zhang,et al.  Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance , 2016, Scientific Reports.

[2]  P. Laurent-Puig,et al.  [Digital PCR compartmentalization I. Single-molecule detection of rare mutations]. , 2015, Medecine sciences : M/S.

[3]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Yang Zhang,et al.  The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations , 2016, OncoTargets and therapy.

[5]  M. Duffy,et al.  p53 as a target for the treatment of cancer. , 2014, Cancer treatment reviews.

[6]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[7]  P. Laurent-Puig,et al.  Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. , 2012, Experimental and molecular pathology.

[8]  P. Nizard,et al.  Assessment of DNA Integrity, Applications for Cancer Research. , 2015, Advances in clinical chemistry.

[9]  S. Laufer,et al.  Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  Yong He,et al.  Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma. , 2015, The Journal of molecular diagnostics : JMD.

[11]  A. Lièvre,et al.  Cetuximab Therapy in Colorectal Cancer Mutation Status Is Predictive of Response to KRAS Updated , 2006 .

[12]  H. Bai,et al.  Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer , 2016, Oncotarget.

[13]  D. Link,et al.  Determining lower limits of detection of digital PCR assays for cancer-related gene mutations , 2014, Biomolecular detection and quantification.

[14]  Qun Zhong,et al.  Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. , 2011, Lab on a chip.

[15]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Klaus Pantel,et al.  Circulating tumor cells: liquid biopsy of cancer. , 2013, Clinical chemistry.

[17]  P. Laurent-Puig,et al.  PCR digitale en micro-compartiments - I. Détection sensible de séquences d’acides nucléiques rares , 2015 .

[18]  Bruno Landi,et al.  Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[19]  Yate-Ching Yuan,et al.  Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy , 2014, Human mutation.

[20]  Allison Hills,et al.  Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. , 2015, Clinical chemistry.

[21]  S H Neoh,et al.  Quantitation of targets for PCR by use of limiting dilution. , 1992, BioTechniques.

[22]  T. Mok,et al.  Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.

[23]  R. McCormack,et al.  Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Tania Nolan,et al.  The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. , 2013, Clinical chemistry.

[25]  J. Pagès,et al.  Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Masahiko Ando,et al.  Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR , 2015, Clinical Cancer Research.

[27]  I. Wistuba,et al.  Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. , 2013, Lung cancer.

[28]  S. Morita,et al.  Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. , 2015, Lung cancer.

[29]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[30]  Peter Ulz,et al.  Circulating tumor DNA as a liquid biopsy for cancer. , 2015, Clinical chemistry.

[31]  Ye Zhang,et al.  The impact of R213 mutation on p53-mediated p21 activity. , 2014, Biochimie.

[32]  J. Kere,et al.  Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. , 2015, Clinical Chemistry.

[33]  A. Shaw,et al.  Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Valérie Taly,et al.  Detecting biomarkers with microdroplet technology. , 2012, Trends in molecular medicine.

[35]  Alexander Dobrovic,et al.  Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations , 2015, Scientific Reports.

[36]  S. Stein,et al.  Circulating Cell-Free Tumour DNA in the Management of Cancer , 2015, International journal of molecular sciences.

[37]  P. Laurent-Puig,et al.  PCR digitale en micro-compartiments - II. Apport pour la détection quantitative d’ADN tumoral circulant , 2015 .

[38]  P. Laurent-Puig,et al.  Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.